ATE359080T1 - Allogene zellkombination enthaltende implantate zur krebsbehandlung - Google Patents
Allogene zellkombination enthaltende implantate zur krebsbehandlungInfo
- Publication number
- ATE359080T1 ATE359080T1 AT98952216T AT98952216T ATE359080T1 AT E359080 T1 ATE359080 T1 AT E359080T1 AT 98952216 T AT98952216 T AT 98952216T AT 98952216 T AT98952216 T AT 98952216T AT E359080 T1 ATE359080 T1 AT E359080T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor
- cancer treatment
- cell combination
- cell population
- alloactivated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title 1
- 239000007943 implant Substances 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/82—Histamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6176697P | 1997-10-10 | 1997-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE359080T1 true ATE359080T1 (de) | 2007-05-15 |
Family
ID=22037992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98952216T ATE359080T1 (de) | 1997-10-10 | 1998-10-09 | Allogene zellkombination enthaltende implantate zur krebsbehandlung |
Country Status (7)
Country | Link |
---|---|
US (1) | US6203787B1 (de) |
EP (1) | EP1021197B1 (de) |
AT (1) | ATE359080T1 (de) |
AU (1) | AU9796998A (de) |
CA (1) | CA2346769C (de) |
DE (1) | DE69837552D1 (de) |
WO (1) | WO1999018981A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080220025A1 (en) * | 1995-03-17 | 2008-09-11 | James Thompson | Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells |
US7361332B2 (en) * | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
EP1037643B1 (de) | 1997-10-10 | 2003-12-03 | Meyer Pharmaceuticals, LLC | Krebsimmuntherapie mittels allostimulierten zellen zur sequentiellen implantationsstrategie |
US6719805B1 (en) * | 1999-06-09 | 2004-04-13 | C. R. Bard, Inc. | Devices and methods for treating tissue |
US7048922B2 (en) * | 2002-05-29 | 2006-05-23 | Demao Yang | Stimulation of hematopoiesis by ex vivo activated immune cells |
US7332158B2 (en) * | 2002-05-29 | 2008-02-19 | Demao Yang | Compositions and treatments for myelosuppression by ex vivo activated immune cells |
US20060057121A1 (en) * | 2004-09-10 | 2006-03-16 | Demao Yang | Compositions and treatments using ex vivo activated cells for myelosuppressed patients |
US20080089875A1 (en) * | 2006-10-13 | 2008-04-17 | Zheng Cui | Methods and compositions for the treatment of cancer |
BRPI0806436A2 (pt) | 2007-01-26 | 2011-09-06 | Univ Lousville Res Foundation Inc | modificação de componentes exossomais para uso como uma vacina |
TW201034641A (en) * | 2009-02-28 | 2010-10-01 | Charles Knezevich | Apparatus, system, and method for creating immunologically enhanced spaces in-vivo |
CN108744262A (zh) * | 2010-11-23 | 2018-11-06 | 普莱萨格生命科学公司 | 用于实体递送的治疗方法和组合物 |
US10035009B2 (en) | 2013-04-15 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treating pancreatic cancer |
BR112017009475B1 (pt) | 2014-11-05 | 2021-10-05 | Memorial Sloan Kettering Cancer Center | Métodos de seleção de uma linhagem de células t e de um doador das mesmas, sistema de computador para selecionar uma linhagem de células t, meio legível por computador, uso de uma população de células t e método para a obtenção de uma linhagem de células t |
US20210196337A1 (en) * | 2019-12-26 | 2021-07-01 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Method for treatment for combination cold atmospheric plasma therapy of solid tumors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192537A (en) | 1984-03-30 | 1993-03-09 | Cellcor Inc. | Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
JP2981486B2 (ja) | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | 哺乳動物の免疫系研究方法 |
WO1991001760A1 (en) | 1989-08-04 | 1991-02-21 | United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Human tumor cells implanted in non-human animals |
US5663481A (en) | 1993-08-06 | 1997-09-02 | Mount Sinai Hospital Corporation | Animal model of the human immune system |
US5476993A (en) | 1993-11-05 | 1995-12-19 | 1002599 Ontario Limited | Pre-treatment of hydrocarbons for preventing spills |
US5602305A (en) | 1994-03-31 | 1997-02-11 | Yale University | Immunodeficient animal model for studying T cell-mediated immune |
JP3822261B2 (ja) | 1994-09-09 | 2006-09-13 | 財団法人癌研究会 | 癌の遺伝子治療剤 |
EP0815204B1 (de) | 1995-03-17 | 2006-09-06 | The Regents Of The University Of California | Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen |
ATE229810T1 (de) | 1996-10-11 | 2003-01-15 | Univ California | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
-
1998
- 1998-10-09 AU AU97969/98A patent/AU9796998A/en not_active Abandoned
- 1998-10-09 WO PCT/US1998/021413 patent/WO1999018981A1/en active IP Right Grant
- 1998-10-09 DE DE69837552T patent/DE69837552D1/de not_active Expired - Lifetime
- 1998-10-09 CA CA002346769A patent/CA2346769C/en not_active Expired - Fee Related
- 1998-10-09 US US09/169,561 patent/US6203787B1/en not_active Expired - Lifetime
- 1998-10-09 AT AT98952216T patent/ATE359080T1/de not_active IP Right Cessation
- 1998-10-09 EP EP98952216A patent/EP1021197B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6203787B1 (en) | 2001-03-20 |
WO1999018981A1 (en) | 1999-04-22 |
EP1021197B1 (de) | 2007-04-11 |
CA2346769A1 (en) | 1999-04-22 |
EP1021197A1 (de) | 2000-07-26 |
AU9796998A (en) | 1999-05-03 |
CA2346769C (en) | 2004-09-14 |
DE69837552D1 (de) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE359080T1 (de) | Allogene zellkombination enthaltende implantate zur krebsbehandlung | |
DK1280552T3 (da) | Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor | |
ATE347366T1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
WO2005086849A3 (en) | Implant scaffold combined with autologous or allogenic tissue | |
DE60123606D1 (en) | Transkutane prothese | |
TR200201442T2 (tr) | Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı. | |
IL115721A0 (en) | Methods and compositions for the modulation of cell proliferation and wound healing | |
EA200200990A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы дельта человека | |
ATE297169T1 (de) | Auffindbare künstliche bioimplantate | |
DE59610355D1 (de) | Medizinisches implantat | |
WO2004009767A3 (en) | Cell therapy for regeneration | |
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
MX2019010725A (es) | Metodos y composiciones para tratar canceres usando antisentido. | |
ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
MXPA02005069A (es) | Agentes de enlace especificos para t3 y metodos para su uso. | |
Veliath et al. | Malignant Pilomatrixoma Report of a Case | |
MX2021005169A (es) | Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido. | |
CA2346735A1 (en) | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy | |
MX2021011760A (es) | Metodos para el tratamiento de canceres usando antisentido. | |
MX2021005168A (es) | Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. | |
PT925064E (pt) | 5-androsteno-3beta,17alfa-diol como um inibidor do crescimento tumoral | |
WO2005094282A3 (en) | Combination therapy comprising cloretazinetm | |
Coquard | Merkel cell carcinoma of the anal canal: importance of radiotherapy | |
Jost et al. | Botulinum toxin A in anal fissure: why does it work? | |
ATE296106T1 (de) | Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |